Inhibitory effect of paclitaxel combined with nedaplatin on HeLa cells transplanted in nude mice
- VernacularTitle:紫杉醇联合奈达铂对HeLa细胞移植瘤生长的影响
- Author:
Meiqin ZHANG
;
Ming YAO
- Publication Type:Journal Article
- Keywords:
cervical cancer;
chemotherapy;
HeLa cells;
animal experiment;
nedaplatin
- From:China Oncology
2006;0(08):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Paclitaxel (Taxol,TXL) combined with cisplatin (DDP) has become the common chemotherapeutic regimen for cervical cancer. However, DDP has higher toxicities. Nedaplatin (NDP), a new platinum analogue,has been shown to have a higher antitumor efficiency against cervical cancer and lower toxicity. This study was done to investigate the antitumor effect of TXL+NDP on HeLa cells transplanted tumor compared with TXL+DDP. Methods:HeLa cells were transplanted subcutaneously in nude mice. These nude mice were randomly divided into 6 groups by sorting when tumor diameter reached 5-6 mm: Control, TXL, NDP,DDP, TXL+NDP,TXL+DDP. Tumor volume and body weight were measured during experiment. The volume ratio (T/ C) was the volume of single agent treatment group and control group and used to assess the antitumor effect, and the combination ratio (CR) was used for the combined therapy. More than 20% weight loss was defined as reaching toxicity level. Results:TXL+NDP regimen had a synergistic antitumor effect (CR=0.76) on HeLa cell transplanted tumor, with a maximum weight loss 8.3%. The tumor volume of TXL+NDP was 172?60 mm3, which was significantly smaller than that of TXL(304?55 mm3) group or NDP(356?67 mm3) group(P0.05), but had a higher toxicity with 4 mice death. Conclusion: TXL+NDP regimen has a synergistic inhibitory effect on HeLa cells and lower toxicity. The efficacy of TXL+NDP regimen needs to be confirmed in clinical trials.
